The MS Trust and NHS Lanarkshire are delighted to announce that they have worked together to recruit two new MS specialist nurses, plus a part-time neurology nurse, to support the 1,200 people living with MS in Lanarkshire. The new nurses will begin work later in September.
The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad) for the treatment of adults with highly active relapsing multiple sclerosis.
The European Medicines Agency has recommended that a licence should be granted for cladribine (Mavenclad) for the treatment of highly active relapsing multiple sclerosis.
A headline in the Daily Mirror makes claims for an experimental treatment that are not yet backed up by research.
The Neurological Alliance, the coalition of 80 organisations working for people with neurological conditions, including the MS Trust, has published a manifesto for neurology services in England.
The launch of a trial involving more than 1000 people with secondary progressive MS (SPMS) has been announced. The trial will investigate whether simvastatin can slow down disability progression.
Emergency hospital admissions for people with MS are on the rise, according to new research published today by the MS Trust and Wilmington Healthcare. These cause distress for people with MS and cost the NHS millions, yet many of them could be avoided.
MS Trust names first sites in specialist nurse funding programme and announces plans to fund a further six new posts in the next year
The Scottish Medicines Consortium (SMC) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.